ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, presented data today from its Phase III program with pimavanserin for Parkinson's disease psychosis, including data from its pivotal -020 Study and the related,...
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, presented data today from its Phase III program with pimavanserin for Parkinson s disease psychosis, including data from its pivotal -020 Study and the related,..
A study commissioned by pharmaceutical group Pharma Dynamics found that students experience negative emotional and psychological effects from allergies in addition to their physical symptoms. Researchers interviewed 800 students in schools across South Africa and observed increased levels of shyness, stress, self-consciousness, embarrassment,...
DUBLIN, Ireland, 2013-06-18 14:00 CEST In accordance with Rule 2.10 of the Irish Takeover Rules, Warner Chilcott plc confirms that, as of the close of business on June 12, 2013, the Company's issued share capital consisted of 251,123,743 ordinary shares, par value US $0.01 per share. The Company Warner Chilcott is a leading specialty pharmaceutic
In China, the process of application and approval for imported drug registration is very complex, because the Chinese pharmaceutical authorities administer and control this process by exorbitant administrative measures and regulations, moreover, these exorbitant administrative regulations are variable and lack of transparency.
China is expected to become the fifth largest drug market in the world by 2010 with a growth rate of 20-25 percent per annum in next three years. As China joins the World Trade Organization and integrates more completely into the global economy, it will further open the door to a lucrative drug market for overseas pharmaceutical companies, which at
In China, the process of application and approval for imported drug registration is very complex, because the Chinese pharmaceutical authorities administer and control this process by exorbitant administrative measures and regulations, moreover, these exorbitant administrative regulations are variable and lack of transparency.
China Pharmaceutical Guidebook Series 2013 Edition. In China, the development of biopharmaceutical industry is far behind the developed countries. In China, the pharmaceutical regulatory authority the SFDA divided the biopharmaceuticals for registration application into two classifications, i.e. the therapeutic biological products and the...
Bandung, Indonesia, June 18, 2013 The 123- year old Indonesian vaccine manufacturer Bio Farma has urged Organization of Islamic Cooperation member countries to be self-reliant in vaccines as imports from industrialized countries are costly. "Some Islamic countries do have their vaccine making companies but they are not yet recognized by the WHO,"
BioAlliance Pharma, a developer of orphan oncology products and supportive care products, has announced the initiation of its Phase II clinical trial evaluating the efficacy and safety of Validive in the United States in patients with chemoradiation therapy-induced oral mucositis with head and neck cancer, as scheduled in the advancement calendar o
By a News Reporter-Staff News Editor at China Weekly News According to news reporting originating from Washington, D.C., by VerticalNews journalists, a U.S. Securities and Exchange Commission filing by Biopharm Asia, Inc. was posted on June 4, 2013. The SEC file number is 9999999997-13-010092.. A U.S. Securities and Exchange Commission filing is
She will report directly to ABPI Chief Executive, Stephen Whitehead and will advise the Senior Leadership Team and Board of Management on communication issues. She will play a pivotal role in communicating to Government the value the pharmaceutical industry brings to the UK, through the creation of life changing medicines and as key driver of econo
biOasis Technologies Inc., an industry-leading provider of technology to potentially deal with the unmet medical need of shuttling therapeutic compounds across the Blood-Brian Barrier, with its Transcend technology, issued the following letter:. The past 12 months have been marked by a number of significant accomplishments. Wilf Jefferies and his t
Various studies have estimated that these anticompetitive agreements cost American consumers between $3 billion and $12 billion every year. The Federal Trade Commission and consumer-rights organizations that have fought Big Pharma on this issue since 1999 are to be congratulated,? said Steve Shadowen of the Austin- based law firm Hilliar
WASHINGTON- Deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can sometimes be illegal and therefore can be challenged in court, the. But "this court's precedents make clear that patent-related settlement agreements can sometimes violate antitr
DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology supportive care products, announced today that it has granted T3D Therapeutics, Inc. the exclusive worldwide rights to develop and commercialize DB959. The T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comp
The Supreme Court ruled Monday that brand-name drugmakers can be sued for violating antitrust laws if they make a deal that pays a potential competitor to put off selling a generic version. The 5-3 decision is likely to benefit consumers with lower prices. The Federal Trade Commission, which has pursued lawsuits against the drugmakers, estimated th
The FDA met with drug makers last week to decide additional safety studies of the drug after reports linking it to pancreatic cancer*. The Journal for the American Medical Association also recently warned that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer****. Now, DrugRisk has learned that the FDA
Livatag is in a Phase III study, RELIVE, which is expected to render final results in 2016. The report identifies a number of earlier catalysts, including the potential partnering of Sitavig for cold sores, which was approved by the FDA in April 2013. Edison has valued BioAlliance at EUR109m based on a risk-adjusted net present value model. Edison
Elan's financial advisers contacted Royalty Pharma's financial advisers over the weekend of 15/ 16 June for the purpose of inviting Royalty Pharma to participate in that process. *Royalty Pharma had sought the approval from the Irish Takeover Panel to allow it to amend its offer so it would not lapse should the Share Repurchase Program or the ELND0
Senior payers from each of the G5 countries of Europe, including representatives from the NHS, G-BA, AIFA, HAS, and the Extremadura region of Spain will discuss with pharmaceutical experts the current state of affairs in each region and also, the best methods and opportunities for the pharmaceutical industry to partner with them. The payers will be
The Halifax Group, a leading middle-market private equity firm, announced today that it has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is an innovative global technology and scientific communication company focused on the pharmaceutical, biotechnology and medical device industries. Envision Pharma has f
Paper offers innovative approaches to bringing drugs to market faster and reducing development costs Raleigh, N.C., June 18, 2013- INC Research, LLC, a therapeutically focused global clinical research organization with a Trusted Process for delivering reliable results, today announced it has released a new white paper titled, "Clinical Process..
Today, Wall Street Reports announced new research reports highlighting Gilead Sciences, Inc., Health Management Associates Inc., IDEXX Laboratories, Inc., ISIS Pharmaceuticals Inc., and Trius Therapeutics Inc.. On June 7, 2013, Gilead Sciences Inc. announced that the US Food and Drug Administration has granted priority review to the New Drug Applic
Saint Laurent, Quebec- IntelGenx Corp. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act action date of February 3, 2014 for the review of the Company's New Drug Application for the marketing approval of IntelGenx' Anti-Migraine VersaFilm? oral film product. The FDA confirmed that IntelGenx
